Methotrexate and salazosulfapyridine in the long term treatment of rheumatoid arthritis

Y. Ichikawa, T. Shinozawa, Tadashi Yoshida, H. Kameda, Y. Suzuki, S. Kawai, H. Yamada, T. Matsuda

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Long term treatment of 190 cases of rheumatoid arthritis with either methotrexate or salazosulfapyridine was analyzed for their efficacy and adverse effects. Both treatment groups showed improvement of clinical symptoms, erythrocyte sedimentation rate, and CRP after 1 month of treatment, while RAHA titers decreased significantly after several months. Erythrocyte sedimentation rate and CRP of salazo-sulfapyridine group, once improved, deteriorated again after 12 months of treatment, while methotrexate group showed sustained improvement for 48 months. Radiologic progression estimated according to JF Fries was significantly less in MTX group than in SASP group. Life table analysis showed that the overall probability of continuing methotrexate or salazosulfapyridine at 4 years was 63% and 55%, respectively. The main reason of treatment termination in methotrexate group was adverse effects, while that in salazo-sulfapyridine group was inefficacy.

Original languageEnglish
Pages (from-to)663-670
Number of pages8
JournalRyumachi
Volume35
Issue number4
Publication statusPublished - 1995
Externally publishedYes

Fingerprint

Sulfasalazine
Methotrexate
Rheumatoid Arthritis
Sulfapyridine
Blood Sedimentation
Life Tables

Keywords

  • life table method
  • long term treatment
  • methotrexate
  • rheumatoid arthritis
  • salazosulfapyridine

ASJC Scopus subject areas

  • Rheumatology

Cite this

Ichikawa, Y., Shinozawa, T., Yoshida, T., Kameda, H., Suzuki, Y., Kawai, S., ... Matsuda, T. (1995). Methotrexate and salazosulfapyridine in the long term treatment of rheumatoid arthritis. Ryumachi, 35(4), 663-670.

Methotrexate and salazosulfapyridine in the long term treatment of rheumatoid arthritis. / Ichikawa, Y.; Shinozawa, T.; Yoshida, Tadashi; Kameda, H.; Suzuki, Y.; Kawai, S.; Yamada, H.; Matsuda, T.

In: Ryumachi, Vol. 35, No. 4, 1995, p. 663-670.

Research output: Contribution to journalArticle

Ichikawa, Y, Shinozawa, T, Yoshida, T, Kameda, H, Suzuki, Y, Kawai, S, Yamada, H & Matsuda, T 1995, 'Methotrexate and salazosulfapyridine in the long term treatment of rheumatoid arthritis', Ryumachi, vol. 35, no. 4, pp. 663-670.
Ichikawa Y, Shinozawa T, Yoshida T, Kameda H, Suzuki Y, Kawai S et al. Methotrexate and salazosulfapyridine in the long term treatment of rheumatoid arthritis. Ryumachi. 1995;35(4):663-670.
Ichikawa, Y. ; Shinozawa, T. ; Yoshida, Tadashi ; Kameda, H. ; Suzuki, Y. ; Kawai, S. ; Yamada, H. ; Matsuda, T. / Methotrexate and salazosulfapyridine in the long term treatment of rheumatoid arthritis. In: Ryumachi. 1995 ; Vol. 35, No. 4. pp. 663-670.
@article{c6586d6bfc3a48228d4fa051e541f3ac,
title = "Methotrexate and salazosulfapyridine in the long term treatment of rheumatoid arthritis",
abstract = "Long term treatment of 190 cases of rheumatoid arthritis with either methotrexate or salazosulfapyridine was analyzed for their efficacy and adverse effects. Both treatment groups showed improvement of clinical symptoms, erythrocyte sedimentation rate, and CRP after 1 month of treatment, while RAHA titers decreased significantly after several months. Erythrocyte sedimentation rate and CRP of salazo-sulfapyridine group, once improved, deteriorated again after 12 months of treatment, while methotrexate group showed sustained improvement for 48 months. Radiologic progression estimated according to JF Fries was significantly less in MTX group than in SASP group. Life table analysis showed that the overall probability of continuing methotrexate or salazosulfapyridine at 4 years was 63{\%} and 55{\%}, respectively. The main reason of treatment termination in methotrexate group was adverse effects, while that in salazo-sulfapyridine group was inefficacy.",
keywords = "life table method, long term treatment, methotrexate, rheumatoid arthritis, salazosulfapyridine",
author = "Y. Ichikawa and T. Shinozawa and Tadashi Yoshida and H. Kameda and Y. Suzuki and S. Kawai and H. Yamada and T. Matsuda",
year = "1995",
language = "English",
volume = "35",
pages = "663--670",
journal = "Ryumachi",
issn = "0300-9157",
publisher = "Nihon Ryumachi Gakkai",
number = "4",

}

TY - JOUR

T1 - Methotrexate and salazosulfapyridine in the long term treatment of rheumatoid arthritis

AU - Ichikawa, Y.

AU - Shinozawa, T.

AU - Yoshida, Tadashi

AU - Kameda, H.

AU - Suzuki, Y.

AU - Kawai, S.

AU - Yamada, H.

AU - Matsuda, T.

PY - 1995

Y1 - 1995

N2 - Long term treatment of 190 cases of rheumatoid arthritis with either methotrexate or salazosulfapyridine was analyzed for their efficacy and adverse effects. Both treatment groups showed improvement of clinical symptoms, erythrocyte sedimentation rate, and CRP after 1 month of treatment, while RAHA titers decreased significantly after several months. Erythrocyte sedimentation rate and CRP of salazo-sulfapyridine group, once improved, deteriorated again after 12 months of treatment, while methotrexate group showed sustained improvement for 48 months. Radiologic progression estimated according to JF Fries was significantly less in MTX group than in SASP group. Life table analysis showed that the overall probability of continuing methotrexate or salazosulfapyridine at 4 years was 63% and 55%, respectively. The main reason of treatment termination in methotrexate group was adverse effects, while that in salazo-sulfapyridine group was inefficacy.

AB - Long term treatment of 190 cases of rheumatoid arthritis with either methotrexate or salazosulfapyridine was analyzed for their efficacy and adverse effects. Both treatment groups showed improvement of clinical symptoms, erythrocyte sedimentation rate, and CRP after 1 month of treatment, while RAHA titers decreased significantly after several months. Erythrocyte sedimentation rate and CRP of salazo-sulfapyridine group, once improved, deteriorated again after 12 months of treatment, while methotrexate group showed sustained improvement for 48 months. Radiologic progression estimated according to JF Fries was significantly less in MTX group than in SASP group. Life table analysis showed that the overall probability of continuing methotrexate or salazosulfapyridine at 4 years was 63% and 55%, respectively. The main reason of treatment termination in methotrexate group was adverse effects, while that in salazo-sulfapyridine group was inefficacy.

KW - life table method

KW - long term treatment

KW - methotrexate

KW - rheumatoid arthritis

KW - salazosulfapyridine

UR - http://www.scopus.com/inward/record.url?scp=0029154448&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029154448&partnerID=8YFLogxK

M3 - Article

C2 - 7482063

AN - SCOPUS:0029154448

VL - 35

SP - 663

EP - 670

JO - Ryumachi

JF - Ryumachi

SN - 0300-9157

IS - 4

ER -